Samsung Bioepis said Friday that global sales of five major biosimilar products increased 30% on-year in the first half of this year, The Korea Herald reported.
Sales of the five biosimilars during the first half reached $166 million, according to an earnings report of its partner Organon International.
Sales of infliximab biosimilar Renflexis reached $81 million, up 37% from $59 million a year earlier, while sales of trastuzumab biosimilar Ontruzant jumped 13% to $45 million during the first half of the year. The breast cancer biosimilar Ontruzant is the first biosimilar of Roche’s Herceptin.
Meanwhile, sales of Eticovo, a biosimilar referencing Pfizer’s Enbrel, decreased 28% during the six-month period.
The sales of the products do not correspond to Samsung Bioepis’ sales as the drugmaker and Organon split earnings as per their contract.
To read more NewsPoints articles, click here.